Gornitzky represented the underwriters in UroGen Pharma’s USD 123.6 million underwritten follow-on public offering on Nasdaq.

Gornitzky represented the underwriters, led by TD Cowen and Guggenheim Securities, in UroGen Pharma Ltd.’s USD 123.6 million underwritten follow-on public offering of shares and pre-funded warrants on Nasdaq.

UroGen is a biotechnology company focused on developing and commercializing innovative treatments for urothelial and specialty cancers.

TD Cowen and Guggenheim Securities acted as joint book-running managers for the offering. Oppenheimer & Co. acted as lead manager for the offering and Ladenburg Thalmann acted as co-manager for the offering.